AbbVie to Acquire Apogee Therapeutics for $10.9 Billion

According to Bloomberg Intelligence analyst Sam Fazeli, AbbVie is acquiring Apogee Therapeutics for $10.9 billion. The deal strengthens AbbVie's presence in dermatology, adding treatments for atopic dermatitis (eczema) to its portfolio and expanding its product range in this area. Fazeli shared his assessment on the Bloomberg Open Interest program. The acquisition is seen as complementary to AbbVie's existing dermatology products. Apogee Therapeutics' pipeline drugs aim to offer new options for treating common skin conditions such as eczema. This strategic move is viewed as part of AbbVie's growth-focused M&A strategy. The company has previously diversified its portfolio through similar deals. Analysts suggest this acquisition could enhance AbbVie's competitive position in the dermatology market. This is not investment advice.

📊 ABBV — Piyasa Yorumu

▲ up · 65%

The news can be considered a positive development that strengthens AbbVie's growth strategy. Technical indicators also support a short-term upward trend: the RSI at 64.9 is not approaching overbought territory, the MACD is above the signal line, and the price is trading above the SMA20 and SMA50. However, caution is warranted due to the high acquisition cost and the market's reaction. A short-term upward movement can be expected, but excessive optimism should be avoided.

RSI 14

64.9

MACD

-1.07

24h Δ

1.93%

Canlı Grafikler